Immunocontraception of white-tailed deer using native and recombinant zona pellucida vaccines

Lowell A. Miller a,*, Brad E. Johns a, Gary J. Killian b

a U.S. Department of Agriculture, National Wildlife Research Center, Fort Collins, CO 80521 USA
b Department of Dairy and Animal Science, Pennsylvania State University, University Park, PA 16802 USA

Received 28 September 1999; received in revised form 25 April 2000; accepted 5 May 2000

Abstract

We conducted a 2-year feasibility study with native porcine zona pellucida (PZP) vaccine and three recombinant rabbit zona pellucida vaccines (RC55, RC75a and a combination of RC55, RC75a and RC75b) as an initial phase of developing a recombinant immunocontraceptive vaccine to control reproduction in overpopulated herds of white-tailed deer (Odocoileus virginianus). Forty captive white-tailed does were divided into five groups (one sham and four treated), of eight each and injected with a 500 mg prime dose of vaccine. Each prime dose was followed by a 300 mg booster dose at 3–7 weeks post prime. The frequency and number of months of observed breeding were higher in PZP immunized does than in sham controls. Although the antibody titers of the three recombinant groups were 1000 or less, as compared with the PZP group with titers often over 128,000, the fawning rates of the two recombinants were significantly lower than that of the control group. The combined antigen group did not have a significantly lower fawning rate. © 2000 Elsevier Science B.V. All rights reserved.

Keywords: Fertility control; Odocoileus virginianus; Porcine zona pellucida; PZP; Recombinant peptide

1. Introduction

Native porcine ZP (PZP) vaccines have produced infertility in various mammals including the rabbit, dog, monkey, horse, burro, and baboon (Kirkpatrick et al., 1990, 1996; Garrott et al., 1992; Turner and Kirkpatrick, 1991; Turner et al., 1996b). Investigators have (Turner et al., 1992, 1996a, 1997; McShea et al., 1997; Miller, 1997; Miller et al., 1999) demonstrated that infertility in white-tailed deer can be accomplished by remotely delivered native PZP. Several scientists have shown that antibodies made to ZP proteins attach to the ZP outer...
surface and block conception by preventing sperm binding and penetration (Sacco et al., 1984; Dunbar and Schwoebel, 1988).

Although PZP extracted from slaughterhouse porcine ovaries provides an excellent tool for understanding immunocontraception, it is neither available nor cost effective for large scale immunization of deer. If the epitopes of the large PZP molecule responsible for producing immunocontraception were determined, it may then be possible to produce them in sufficient quantity to make a PZP based vaccine for wide scale use. Skinner et al. (1994), identified three proteins from the rabbit ZP that have immuno cross-reactivity with native PZP. The three recombinant proteins, RC55, RC75a, and RC75b were cloned into an *Escherichia coli* (*E. coli*) vector and were expressed fused with a β-galactosidase and removed from the *E. coli* by the French press technique (Schwoebel et al., 1991). The mass of RC55 is 55 kDa, RC75a and RC75b, the components of RC75 have a combined mass of 75 kDa.

This paper reports the first attempt to use a recombinant rabbit ZP to immunocontracept white-tailed deer. The rabbit ZP glycoproteins are immunologically similar to other mammalian ZP, including the pig, cat, dog, baboon, deer, and human (Maresh and Dunbar, 1987; Paterson et al., 1996; Prasad et al., 1996).

2. Materials and methods

This immunocontraceptive study was part of a multi-year white-tailed deer infertility study on the deer herd at Pennsylvania State University (PSU), University Park, Pennsylvania in cooperation with National Wildlife Research Center (NWRC), Fort Collins, CO. The animals in the study were in a 17 acre fenced facility containing several paddocks for separation of study groups. The facility has holding pens which allows the deer to be accessed for injection and blood collections.

Forty white-tailed does were divided randomly into five groups of eight each and injected subcutaneously with 1 ml of vaccine distributed among several sites at the center of the back between the scapulae. This 1 ml prime dose contained 500 μg of antigen preparation as follows: Group 1 (control) in year 1, physiological saline in complete Freund’s adjuvant (CFA); in year 2, with eight different deer, β-galactosidase (as a control for the β-galactosidase fused to the recombinants) in CFA; Group 2 (PZP) porcine zona pellucida in CFA; Group 3 (RC55), recombinantly produced rabbit ZP protein in CFA; Group 4 (RC75a), recombinantly produced rabbit ZP protein in CFA; and Group 5 (RC55, RC75a, and RC75b), equal quantities of three recombinantly produced rabbit ZP proteins in CFA. Group 4 was only tested in year 2 and Group 5 only in year 1. Each 500 μg prime dose was followed by a 300 μg booster dose of 1 ml at 3–7 weeks post prime dose administration in incomplete Freund’s adjuvant (IFA). The research paradigm is shown in Fig. 1. CFA and IFA were obtained from Calbiochem®, La Jolla, CA. All deer were tranquilized with 0.5–1.0 ml of xylazine before blood sampling and vaccination. One of the eight deer in Group 3 (RC55) died in the first year before data could be collected and it was replaced for the second year. In the second year, another doe in the same group died after data were collected through December. Neither of the deaths exhibited any pathology that was related to RC55 treatment.
Fig. 1. Schedule of white-tailed deer vaccination, bleeding and breeding. Quantity of antigen per vaccination and type adjuvant. CFA=complete Freund’s adjuvant, IFA=incomplete Freund’s adjuvant.

The PZP and recombinant ZP antigens were prepared as previously reported (Wood et al., 1981; Skinner et al., 1994) via a contract with Dr. B.S. Dunbar’s laboratory at the Baylor College of Medicine, Houston, TX. Rabbit recombinant antigens were expressed in a pEX-2 E. coli vector as a cro-β-galactosidase fusion protein. To increase their immunogenicity, these expressed proteins were conjugated to Protein A by a single step glutaraldehyde technique, the first year and conjugated by the EDC method to keyhole limpet hemocyanin (KLH) the second year.

Blood samples were taken just prior to administration of the prime and second booster injections, and several times after vaccinations. Serum was analyzed by ELISA to assess the immune response to the treatments. ELISA antibody titers were considered the highest serum dilution at which the end point color was three times background. Plasma progesterone levels were assayed by the coat-a-tube RIA method (Diagnostic Products, Los Angeles, CA). The does from all groups were put in with three bucks in 17 acres of fenced in area and allowed to breed under natural conditions. The estrous activity or rutting behavior of the treated deer was compared with control deer in the open pen natural setting. Breeding observations were conducted for 2 h each time, three times daily from 7 November to 12 February, and then two times daily until 28 February. Estrous activity was considered as any of the following behavior of males toward females: vaginal sniffing, pursuit, aggressive guarding, and mounting and copulation. Natality was observed for all groups.

Pregnancy detection was performed by ultrasound in late January and by palpation in late March or early April to determine, if conditions that would result in abortion or reabsorption of the fetus were involved in any treatment effects.

In the ELISA analysis, 100 ng of native PZP antigen were used to coat each micro titer plate well. Deer serum was serially diluted from 1:1000 to 1:128000 with phosphate
buffered saline. Antibodies in the deer serum bound to the native PZP antigen on the plate were detected by rabbit anti-deer IgG followed by goat anti-rabbit IgG horseradish peroxidase. The chromogen tetramethylbenzidine was used as a substrate and 2 M H₂SO₄ was used to stop the reaction. The color intensity of the sample was read at 450 nm with a Dynatech MR 2000 ELISA plate reader. Serum from deer immunized with recombinant ZP was tested for reactivity to recombinant ZP in addition to native ZP. Thus, if the serum antibody cross-reactivity to PZP appeared weak, a check was made to be sure vaccination with the recombinants was providing a good immune response to the injected immunogen. Data was analyzed by unpaired Student’s T-test.

3. Results

3.1. Behavioral data

Most control deer in the study mated at the first observed estrous, (determined by the fawning data) and breeding was completed during the month of November. One or two estrous events were observed on average for each control doe during the breeding period lasting 44 days. Recombinant treated deer did not demonstrate behavior different from the control deer (P>0.05). However, the PZP-treated does were observed to have 1–4 sexual encounters per doe (mean = 3.6), and remained sexually active over 98 days. (P<0.05) Several does exhibited sexual activity in January and February.

3.2. Fawning data

During the study, the five groups of does produced the following total numbers of fawns (Fig. 2): The control group had 30 fawns with 1.88±0.08 fawns/doe (mean±SEM); PZP-treated does have four fawns with 0.25±0.14 fawns/doe, a 87% reduction in fawning (P<0.0001); The RC55-treated group had 19 fawns with 1.26±0.23 fawns/doe, a 33% reduction in fawning (P<0.05); The RC75a-group had 11 fawns (1 year) with 1.37±0.18 fawns/doe, a 27% reduction in fawning (P<0.01); and combined RC55, RC75a, RC75b (1 year) had 16 fawns with 2.0±0.27 fawns/doe, no reduction in fawning (P>0.05). The β-galactosidase group had no reduction in fawning (P>0.05). The P values of all treated groups were determined in relation to the control group.

During the first year, 23 untreated normal does housed at the Penn State facility, but not in the study, had a mean fawning date 25±1.7 days (mean±SEM) of May. During year 2, a similar group of 21 does, not in the study had a mean fawning date 31±2.5 days of May. These data are representative of normal fawning rates for the Penn State herd. In the combined 2 years of this study, the 16 (Group 1) control deer had a mean fawning date 5±6.6 days of June. (Fig. 2). If the two late fawnings were removed (logic presented in discussion), the mean fawning date was 27±1.8 days of May. Therefore, the Group 1 controls do not appear to meaningfully differ in fawning date from normal reference does. The only group deviating from this fawning pattern was the Group 2 PZP-treated does which had a mean fawning date 16±16.1 days of July with none before 15 June (P<0.05).
Assuming an average gestation of 200 days, breeding of control does occurred within a 4-week period, beginning the last week of October through the third week of November with the exception of two does that have estimated breeding dates of 11 January and 1 February. One of these two does, first had a progesterone level that was indicative of being ready to breed in mid December, but did not breed until January, when the progesterone value was still at a breeding status. The other doe did not have a progesterone level, suggestive of readiness to breed until mid January.

Five of the PZP-treated group did not conceive the first year. The three that conceived were late in conceiving; births occurred 15 June, 26 July, and 7 August. Assuming a 200-day gestation, the later two conceived 7 January, and 19 January, up to 62 days or 2–3 estrous cycles after the last control doe bred on 18 November. The mean breeding date for the control does was 5 November and for the PZP-does 29 December, a 54 day difference. After vaccination in the second year, there were no fawns conceived in the PZP group. All 12 of the positive pregnancy determinations by palpation, the first year resulted in fawn births and all 18 of the 18 positive pregnancy examinations by ultrasound, the second year resulted in births. No aborted fetuses were observed in either year. Although, not unequivocal data for the entire period of pregnancy or the study population, these results demonstrate that there were no apparent abortions or reabsorption of fetuses in 30 does observed during the study.

3.3. Antibody titers

There was a high antibody response to native PZP, in Group 2, (the PZP deer) with many titers over 128K, all 8 does had antibody titers over 128K in at least one bleeding (Fig. 3). In Groups 3 and 4, the deer receiving RC55 and RC75a, had antibody titers of non-detectable to 1K to native PZP. However, when serums of Groups 3 and 4 were tested
Against RC55 and RC75a proteins, titers of over 64K were observed. Much of the immune response to the recombinant vaccine may have been due to contaminating bacterial proteins and carrier proteins in these preparations, with very little antibody to RC55 and RC75a antigens themselves. Group 5 (RC55, RC75a, and RC75b) did not demonstrate any antibody response.

During the first year, the Group 2 PZP peak antibody titers were at least 128K in seven of eight deer, and 32K in the remaining deer at the 7 October bleeding. The titer in three of the eight deer then dropped to 24–64K by the 4 November bleeding at the time of the initial estrous in the breeding season (Fig. 1). Titors in four of the other five deer stayed at 128K and one at 96K. Two of the three deer with the lower November titers conceived late fawns (one with 1 and the other 2), indicating that they did become fertile at some point after November when the titers would still be dropping. The third doe did not fawn. Also, one of the five deer with high titers 4 November had one fawn late, indicating its titer also dropped after November. During the second year, the PZP-treated deer of Group 2 were immunized, starting one month later in order to boost and sustain the immune response at a maximum through the breeding period. This resulted in titers greater than 128K on the 4 November bleed date and complete contraception of all eight deer. Fig. 4 is a summary of peak titers for both study years. In Group 2 (PZP), the antibody titer that is effective in preventing conception at the critical point in the estrous cycle appears to be 24–64K.

4. Discussion

The fact that 14 of 16 control does in Group 1 conceived within 4 weeks of exposure to bucks, and all produced twins (Fig. 2), indicates that handling and injecting the deer did not interfere with their normal reproductive capacity.
The observation that native PZP immunization was highly effective in reducing reproductive capacity (Fig. 2) is consistent with the data reported by Turner et al. (1992, 1996a,b). Vaccination with RC55 resulted in a significant reduction in fertility ($P<0.05$). Two does failed to conceive and an additional 43% of the remaining does had only one fawn. RC75a-vaccinated does showed a significant reduction in fertility ($P<0.01$). Although, no does were infertile, 63% of the does produced only one fawn. Interestingly, the combined rabbit recombinants RC55, RC75a and RC75b vaccine had no reducing effect on the number of fawns. It is also noteworthy that 12 of the 13 single fawns produced by the three RC groups were born in the time period of normal fawning for the Penn State herd.

The peak PZP antibody titers in the first year, occurred at the 7 October bleed in Group 2 and were already showing a decline by the 4 November bleed (Fig. 3). Since three does did fawn, it is likely that the initial antibody titers prevented conception but as they dropped below a critical level, contraception was not maintained. The second year, when the peak titers were achieved in November and sustained into January, all of the PZP-treated does were infertile.

In its native form PZP is a large three dimensional glycoslated structure with hydrophilic attributes which when used as an immunogen presents epitopes that stimulate the immunoc contraceptive response. Skinner et al. (1994), using SDS-gel electrophoresis and western blotting, demonstrated that deer injected with PZP formed antibodies that cross-reacted with RC55, RC75a and RC75b. These observations are consistent with data of Yurewicz et al. (1993) who demonstrate that the PZP3a portion of the PZP molecule shares a 66% overall protein sequence identity with a 55 kDa rabbit zona protein. However, when the RC55 protein was used as an immunoc contraceptive vaccine in the present study, the deer produced little PZP cross-reactive antibody.
It is possible, because of the way the recombinantly produced rabbit ZP epitopes were presented to the immune system, that the immune response was predominately produced against the co-expressed β-galactosidase, and the carrier protein A. Antibody data tends to support this hypothesis. High titers are demonstrated in the deer serum when the entire conjugate recombinant vaccine (RC-ZP peptides, β-galactosidase, and protein A) is bound to the ELISA plate, but there are few cross-reacting antibodies, in the same serum, to native PZP when it is bound to the plate. Also, the E. coli expressed recombinant ZP proteins, are very hydrophobic and precipitate in an aqueous media, raising the possibility that key epitopes may not be presented properly to the immune system.

Because our data show that the recombinantly produced rabbit ZP proteins used to vaccinate deer result in low antibody titers to the native PZP on the ELISA plate, the recombinant forms must lack either or both the conformation or glycosylation that results in antibodies that cross-react with the native PZP molecule.

The reduced immunocontraceptive effectiveness of Group 5 (combined RC55, RC75a and RC75b) can only be speculated. It is possible that the three antigens bonded together in such a manner that the epitopes required for contraception in each antigen were covered and not accessible to the immune system.

5. Conclusions

Rabbit recombinant ZP peptides RC55 and RC75 were compared with native PZP as contraceptive vaccines in the white-tailed deer. Both of the rabbit recombinants reduced fertility although they were not as effective at native PZP. Since, these recombinant peptide reduced fertility, the peptides apparently contain contraceptive epitopes, even though there was little immunological cross reactivity to the native PZP as measured by ELISA. The presentation of these ZP peptides may be improved by removing the contaminating bacterial expression proteins.

One must conclude that it takes small quantities of antibody to block sperm penetration at the ova level and that the in vivo activity is more sensitive than the in vitro ELISA method.

References


